AP1287A - Treatment of diabetes with rosiglitazone and insulin. - Google Patents

Treatment of diabetes with rosiglitazone and insulin. Download PDF

Info

Publication number
AP1287A
AP1287A APAP/P/1999/001718A AP9901718A AP1287A AP 1287 A AP1287 A AP 1287A AP 9901718 A AP9901718 A AP 9901718A AP 1287 A AP1287 A AP 1287A
Authority
AP
ARIPO
Prior art keywords
compound
pharmaceutically acceptable
insulin
acceptable form
diabetes mellitus
Prior art date
Application number
APAP/P/1999/001718A
Other languages
English (en)
Other versions
AP9901718A0 (en
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9901718A0 publication Critical patent/AP9901718A0/xx
Application granted granted Critical
Publication of AP1287A publication Critical patent/AP1287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/1999/001718A 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin. AP1287A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (2)

Publication Number Publication Date
AP9901718A0 AP9901718A0 (en) 1999-12-31
AP1287A true AP1287A (en) 2004-06-26

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001718A AP1287A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin.

Country Status (30)

Country Link
EP (1) EP0999837A1 (el)
JP (1) JP2002504138A (el)
KR (1) KR20010013843A (el)
CN (1) CN1133431C (el)
AP (1) AP1287A (el)
AR (2) AR012997A1 (el)
AU (1) AU8216398A (el)
BG (1) BG104059A (el)
BR (1) BR9810444A (el)
CA (1) CA2294141A1 (el)
CO (1) CO4940454A1 (el)
DZ (1) DZ2521A1 (el)
EA (1) EA004800B1 (el)
GB (1) GB9712866D0 (el)
HU (1) HUP0003260A3 (el)
ID (1) ID23951A (el)
IL (1) IL133143A0 (el)
IN (1) IN189723B (el)
MA (1) MA26511A1 (el)
NO (1) NO996265L (el)
OA (1) OA11517A (el)
PE (1) PE104499A1 (el)
PL (1) PL343123A1 (el)
SK (1) SK179399A3 (el)
TR (1) TR199903095T2 (el)
TW (1) TW587937B (el)
UA (1) UA70299C2 (el)
UY (1) UY25050A1 (el)
WO (1) WO1998057636A1 (el)
ZA (1) ZA985237B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
PT1173434E (pt) 1999-04-23 2003-12-31 Smithkline Beecham Plc Novo produto farmaceutico
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (es) 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Also Published As

Publication number Publication date
IN189723B (el) 2003-04-19
NO996265D0 (no) 1999-12-17
AR012997A1 (es) 2000-11-22
UY25050A1 (es) 2000-09-29
CO4940454A1 (es) 2000-07-24
ZA985237B (en) 2000-02-17
IL133143A0 (en) 2001-03-19
MA26511A1 (fr) 2004-12-20
SK179399A3 (en) 2000-11-07
EA004800B1 (ru) 2004-08-26
BR9810444A (pt) 2000-09-05
AP9901718A0 (en) 1999-12-31
CN1133431C (zh) 2004-01-07
NO996265L (no) 1999-12-17
TR199903095T2 (xx) 2000-08-21
HUP0003260A2 (hu) 2001-05-28
EP0999837A1 (en) 2000-05-17
BG104059A (en) 2000-10-31
ID23951A (id) 2000-06-08
GB9712866D0 (en) 1997-08-20
AR015894A1 (es) 2001-05-30
CA2294141A1 (en) 1998-12-23
AU8216398A (en) 1999-01-04
DZ2521A1 (fr) 2003-02-08
OA11517A (en) 2004-02-04
PL343123A1 (en) 2001-07-30
WO1998057636A1 (en) 1998-12-23
HUP0003260A3 (en) 2001-12-28
TW587937B (en) 2004-05-21
CN1260715A (zh) 2000-07-19
KR20010013843A (ko) 2001-02-26
PE104499A1 (es) 2000-01-13
JP2002504138A (ja) 2002-02-05
UA70299C2 (en) 2004-10-15
EA200000042A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
EP0996444B1 (en) Treatment of diabetes with thiazolidinedione and metformin
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
US20050059706A1 (en) Treatment of diabetes with thiazolidinedione and metformin
CA2292629C (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20030187030A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP0999845B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
EP0998291B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ501345A (en) Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
US20030073645A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin